Case Summary (G.R. No. 174371)
Applicable Law
The case centers around Republic Act No. 7432, also known as "An Act to Maximize the Contribution of Senior Citizens to Nation Building," which grants senior citizens a 20% discount on various purchases, including medicines. The law stipulates that private establishments may claim the cost of the discount as a tax credit.
Background of Claims and Tax Refunds
Mercury Drug Corporation granted a 20% sales discount to qualified senior citizens in compliance with RA 7432. For the taxable years 1993 and 1994, the total discounts amounted to P3,719,287.68 and P35,500,593.44, respectively. The corporation sought to claim these amounts as deductions from its gross income and subsequently filed claims for refund with the CIR for perceived overpayments in its income tax.
Initial Rulings by the Court of Tax Appeals
When the CIR did not act on the claims, Mercury Drug Corporation pursued its case in the Court of Tax Appeals (CTA). On September 6, 2000, the CTA partially granted the petition, ruling that the 20% sales discount should be classified as a tax credit rather than a mere deduction from gross income. However, the CTA also identified discrepancies in the cash slips, which led to a denial of claims for 1994 and partial reductions for 1993.
Disputed Computation of Tax Credits
The CTA's decision required adjustments in the amounts representing the discounts given to senior citizens. The allowed tax credits for the taxable years were recalculated, resulting in a tax credit of P1,688,178.43 for 1993 and no refund for the 1994 tax year due to the business incurring a tax due instead of a credit.
Petitioner’s Contentions on Appeal
The petitioner then elevated the case to the Court of Appeals, arguing that the computations should be based on the total discount granted rather than just the cost of goods sold or acquired. The Court of Appeals affirmed the CTA's ruling, aligning with previous court interpretations that defined the term "acosta" to mean the cost of medicines.
Legal Grounds Raised by Petitioner
In its petition, Mercury Drug Corporation raised several legal grounds, including claims of a taking of property without just compensation, violations of due process, and unequal treatment compared to other establishments. The petitioner contended that the discount should encompass all costs incurred, not just the direct acquisition cost.
Office of the Solicitor General's Stance
The Office of the Solicitor General supported the petitioner's stance, advocating for the computation of tax credits based on the full 20% sales discount rather than limited to acquisition costs. They referenced related case law, asserting that the actual amount of the discount should serve as the basis for tax credit calculations.
Supreme Court's Rationale and Judgment
Upon review, the Supr
...continue readingCase Syllabus (G.R. No. 174371)
Background and Facts
- Petitioner, Mercury Drug Corporation, a retailer of pharmaceutical products, granted a 20% sales discount to qualified senior citizens pursuant to Republic Act No. 7432.
- For the taxable years April to December 1993 and January to December 1994, petitioner claimed as deductions from gross income the amounts of P3,719,287.68 and P35,500,593.44 respectively representing the 20% sales discounts granted.
- Petitioner filed claims for refund with the Commissioner of Internal Revenue (CIR) amounting to P2,417,536.00 (1993) and P23,075,386.00 (1994) based on the tax credit allowed under the law.
- The CIR failed to act on these claims, prompting petitioner to file a petition for review with the Court of Tax Appeals.
Court of Tax Appeals Ruling
- On 6 September 2000, the Court of Tax Appeals partially granted the petition, declaring Revenue Regulations No. 2-94 null and void insofar as it treated the 20% discount as a deduction from gross sales.
- The Court held the 20% sales discount should be treated as a tax credit.
- However, due to discrepancies and irregularities found in petitioner’s cash slips, the tax refund claim for 1994 was denied and the claimed amount for 1993 was reduced.
- The Court applied a formula limiting the tax credit to the acquisition cost of the 20% discount (cost of sales divided by gross sales multiplied by discount amount), not the full discount amount.
- The Court allowed a reduced tax credit: P1,688,178.43 for 1993 and denied refund for 1994.
Resolution on Reconsideration by Court of Tax Appeals
- On 20 December 2000, the Court modified its ruling and increased the creditable tax amount to P18,038,489.71 covering both years.
- It granted the 1994 refund claim in the amount of P16,350,311.28 based on properly substantiated cash slips.
Court of Appeals Decision
- On 20 October 2003, the Court of Appeals affirmed the Court of Tax Appeals’ resolution, adopting the interpretation of "acosta" as the acquisition cost of medicines sold to senior citizens.
- The Court relied on previous decisions, particularly Commissioner of Internal Revenue v. Elmas Drug Corporation, to sustain that tax credit computation should be based on acquisition cost.
- Petitioner’s motion for partial reconsideration was denied on 23 June 2004.
Legal Issues Raised by Petitioner
- Limiting tax credit only to acquisition cost constitutes taking without just compensation.
- Requirement to grant 20% discount without full re